Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Zendy

Julie R. Brahmer | Zendy; Scott S. Tykodi | Zendy; Laura Q.M. Chow | Zendy; Wen-Jen Hwu | Zendy; Suzanne L. Topalian | Zendy; Patrick Hwu | Zendy; Charles G. Drake | Zendy; Luis H. Camacho | Zendy; John S. Kauh | Zendy; Kunle Odunsi | Zendy; Henry C. Pitot | Zendy; Omid Hamid | Zendy; Shailender Bhatia | Zendy; Renato Martins | Zendy; Keith D. Eaton | Zendy; Shuming Chen | Zendy; Theresa M. Salay | Zendy; Suresh Alaparthy | Zendy; Joseph F. Grosso | Zendy; Alan J. Korman | Zendy; Susan Parker | Zendy; Shruti Agrawal | Zendy; S. Goldberg | Zendy; Drew M. Pardoll | Zendy; Ashok Gupta | Zendy; Jon M. Wigginton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Author(s) -

Julie R. Brahmer,

Scott S. Tykodi,

Laura Q.M. Chow,

Wen-Jen Hwu,

Suzanne L. Topalian,

Patrick Hwu,

Charles G. Drake,

Luis H. Camacho,

John S. Kauh,

Kunle Odunsi,

Henry C. Pitot,

Omid Hamid,

Shailender Bhatia,

Renato Martins,

Keith D. Eaton,

Shuming Chen,

Theresa M. Salay,

Suresh Alaparthy,

Joseph F. Grosso,

Alan J. Korman,

Susan Parker,

Shruti Agrawal,

S. Goldberg,

Drew M. Pardoll,

Ashok Gupta,

Jon M. Wigginton

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1200694

Subject(s) - blockade , immune system , pd l1 , medicine , antibody , in vitro , cancer , cancer research , receptor , immune checkpoint , programmed cell death , immunology , function (biology) , cancer cell , immunotherapy , apoptosis , microbiology and biotechnology , biology , biochemistry

Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research